Relatlimab
- Generic Name
- Relatlimab
- Brand Names
- Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1673516-98-7
- Unique Ingredient Identifier
- AF75XOF6W3
- Background
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint inhibit...
- Indication
Relatlimab is indicated in combination with nivolumab, in the combination product Opdualag, for the treatment of adult and pediatric patients โฅ12 years old with unresectable or metastatic melanoma.
- Associated Conditions
- Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06683755
- Locations
- ๐บ๐ธ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 800
- Registration Number
- NCT06561386
- Locations
- ๐บ๐ธ
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
๐บ๐ธLocal Institution - 0369, Canton, Ohio, United States
๐ง๐ทLocal Institution - 0382, Fortaleza, Cearรก, Brazil
Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT06325683
- Locations
- ๐บ๐ธ
Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธSutter Auburn Faith Hospital, Auburn, California, United States
๐บ๐ธKaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06237920
- Locations
- ๐ณ๐ฑ
NKI-AVL, Amsterdam, Noord-Holland, Netherlands
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT06029270
- Locations
- ๐บ๐ธ
Oncology Associates PC, Omaha, Nebraska, United States
๐บ๐ธKaiser Permanente Dublin, Dublin, California, United States
๐บ๐ธKaiser Permanente-Fremont, Fremont, California, United States
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1190
- Registration Number
- NCT05987241
- Locations
- ๐บ๐ธ
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
๐บ๐ธCancer Center at Saint Joseph's, Phoenix, Arizona, United States
๐บ๐ธUniversity of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05704647
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Immunotherapy in Patients with Carcinomas Arising from the Renal Medulla
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05347212
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 162
- Registration Number
- NCT05337137
- Locations
- ๐ฆ๐บ
Royal Adelaide Hospital, Adelaide, South Australia, Australia
๐ซ๐ทCHU de Reims-Hopital Robert Debre, Reims, France
๐ญ๐ฐThe Chinese University of Hong Kong Prince of Wales Hospital, Shatin, Hong Kong
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT05255601
- Locations
- ๐ฎ๐น
Local Institution - 0010, Aviano, Italy
๐ฎ๐นLocal Institution - 0007, Bologna, Italy
๐ฎ๐นAzienda Ospedaliero Universitaria Meyer, Florence, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.